# Harrison.ai

> Harrison.ai is a Sydney-based clinical AI company founded in 2018 by brothers Dr Aengus Tran and Dimitry Tran. It builds artificial-intelligence software that helps clinicians read medical images faster and more accurately - flagging urgent findings on chest X-rays and brain and chest CT scans, and streamlining pathology review. Its diagnostic products, radiology brand annalise.ai and pathology joint venture franklin.ai, are used at more than 1,000 healthcare sites across four continents, with regulatory clearance in 40-plus countries. The company positions itself as a builder of foundation models for medicine, releasing harrison.rad.1, a radiology-specific multimodal large language model. Harrison.ai raised a US$112 million Series C in February 2025 to fund a US expansion, taking total capital raised past US$240 million.

- **Founded:** 2018
- **Headquarters:** Sydney, Australia
- **Founders:** Dr Aengus Tran (Co-Founder and CEO), Dimitry Tran (Co-Founder and Managing Director, Americas)
- **Team size:** Approximately 230 employees
- **Products:** annalise.ai (Radiology), franklin.ai (Pathology), harrison.rad.1, Open Platform
- **Notable:** 12 FDA clearances across chest X-ray and brain/chest CT modalities, Regulatory clearance in 40+ countries and distribution across 15 countries, Deployed at 1,000+ healthcare sites across four continents

## Products & services

- **annalise.ai (Radiology)** — AI decision-support and triage software for medical imaging. It analyses chest X-rays and brain and chest CT scans, flags urgent findings for prioritisation and generates draft structured reports. Holds 12 FDA clearances across chest and brain modalities and supports over 6 million patients a year.
- **franklin.ai (Pathology)** — Joint venture with Sonic Healthcare bringing AI support to digital pathology, helping pathologists diagnose more accurately and efficiently. First product focuses on prostate biopsy.
- **harrison.rad.1** — A radiology-specific multimodal large language model that can answer open visual questions about radiology images, detect findings and generate structured reports - positioned as a foundation model building block for healthcare AI.
- **Open Platform** — A marketplace approach that lets healthcare providers access third-party AI tools (such as Lunit for oncology) alongside Harrison.ai's own models through a single integration.

## Achievements

- 12 FDA clearances across chest X-ray and brain/chest CT modalities
- Regulatory clearance in 40+ countries and distribution across 15 countries
- Deployed at 1,000+ healthcare sites across four continents
- annalise.ai supports the care of more than 6 million patients per year
- 12+ million medical imaging cases analysed
- FDA Breakthrough Device Designation and Medicare NTAP reimbursement for a CT brain algorithm
- Named to Time's list of the world's top healthtech companies of 2025
- Raised US$240M+ in total capital

## Latest updates

- **2025-02** — Raised US$112 million Series C co-led by Aware Super, ECP Asset Management and Horizons Ventures to accelerate expansion into the United States, establishing a North American base in Boston.
- **2025-04** — annalise.ai received additional FDA clearance for chest X-ray triage, extending its US portfolio of cleared findings.
- **2024** — Launched harrison.rad.1, a radiology-specific multimodal large language model, and expanded its Open Platform with new third-party AI partners including Lunit.
- **2026-05** — Featured in Forbes as a doctor-turned-entrepreneur story on Dr Aengus Tran using AI to save lives.

## Links

- Website: https://harrison.ai
- LinkedIn: http://www.linkedin.com/company/harrison-ai
- Twitter/X: https://x.com/harrison_ai

---

Profile page: https://yespress.io/harrison-ai
Published by YesPress — https://yespress.io
Last updated: 2026-07-27